Digital healthcare firm Clarius Mobile Health has secured approval from the US Food and Drug Administration (FDA) for its C3 and L7 Clarius wireless ultrasound scanners.
Launched in March this year, the scanners will enable clinicians to carry out quick scans and guide short procedures at the bedside.
Clarius C3 multipurpose ultrasound scanner has been developed to image the abdomen and lungs. It also integrates virtual phased array for quick scans of the heart.
The company designed Clarius L7 ultrasound scanner for guiding procedures and imaging superficial structures.
The ultrasound scanners are compatible with the latest iOS and Android smartphones and tablets.
Clarius scanners include rechargeable battery that can be replaced when running low, while most of the other app-based ultrasound systems receive power from a connected smart device.
The ultrasound scanners, which are resistant to water for easy cleaning and sterilization, have been built with magnesium case to work in challenging environments.
Clarius Mobile Health chairman and CEO Laurent Pelissier said: "Receiving 510(k) Clearance for our Clarius Scanners is a significant milestone for our company.
"There appears to be a growing trend of digital healthcare companies receiving FDA clearance for innovations designed to deliver more efficient patient care.
“We are delighted to bring a new class of affordable and easy to use ultrasound to the medical community in the United States."